The Haystack Project
  • Home
  • About Us Participants Partners Board and Advisors
  • Priorities
  • PROTECT Rare
  • Modernizing-FDA HEART Act
  • Speaker Series Payer Engagement Health Equity Patient Oriented Value Rare Cancer
  • Inflation Reduction Act Medicare Section 340b Medicaid FDA ICER
  • Patient Stories
  • Join
  • Take Action
The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Modernizing-FDA
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Patient Oriented Value
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
Blue-Banner.png
The Haystack Project

Health Equity in Access to Treatment

The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Modernizing-FDA
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Patient Oriented Value
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/

 
heat logo-01.png
 

Haystack Project works on solving for a health system not designed to fully consider the lived experience of rare and ultra-rare patients.  As COVID-19 cast a spotlight on the profound impact that racial and geographic inequities have on health outcomes, Haystack’s participating advocacy organizations asked for support in illuminating and addressing the needs of historically underserved patients and their communities.

First HEAT Report Released

Haystack Project and the Siegel Rare Neuroimmune Association (SRNA) released the first Health Equity in Access to Treatments (HEAT) Report for Neuromyelitis Optica Spectrum Disorder (NMOSD). The report highlights disparities in access to timely diagnosis, treatments, and specialist care, particularly among patients in rural or low-income communities. Survey findings revealed that nearly one in five patients could not access FDA-approved therapies recommended by their clinicians, often due to insurance “step therapy” barriers. Patients also reported delayed diagnoses, high levels of disability within the first few years of disease onset, and unequal access to care depending on presenting symptoms and geographic location.

The HEAT Report provides data-driven recommendations to improve equity, increase outreach to underserved populations, and support SRNA’s mission to strengthen advocacy and education for the NMOSD community.

Read the full HEAT Report here
Read the full Press Release here

 
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Modernizing-FDA
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Patient Oriented Value
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/

The Haystack Project

Act Now

Engage in our efforts to support Rare disease advocacy.

Act Now
 

Join Haystack Project

Get news and updates and engage in rare disease advocacy. Sign up to join our community today.

Join Us
 

Keep up-to-date with current events at Haystack!

View past newsletters

About Us

The Issues

Resources

News & Updates

© 2020 Haystack Project. All Rights Reserved. 

 

Contact Us

Please consider making a tax-deductible donation to support the Haystack Project today.

The Haystack Project is a 501(c)3 nonprofit that brings together patients organizations representing patients suffering from or caring for patients with extremely rare diseases. Our mission is to educate policymakers and other stakeholders about the need for policies that recognize the unique circumstances of extremely rare conditions and treatments and expand incentives critical to ensuring they can reach patients.